Janssen Pharmaceutical to supply up to 400 million Covid-19 vaccine doses to EU
The deal also includes an option that allows supply of up to 200 million additional doses to the EU member states. This agreement was signed after the conclusion
Johnson & Johnson has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of nipocalimab, aimed at treating individuals with generalied myasthenia gravis (gMG).
Under the deal, Scribe Therapeutics and Biogen will develop and commercialise CRISPR-based therapies to treat amyotrophic lateral sclerosis (ALS). X-Editing (XE), which is Scribe’s first technology, is said
“The FDA’s designation recognizes the morbidity and mortality burdens of sickle cell disease as well as its significant impact during childhood with life-long implications. With this designation, the